Cintredekin Besudotox
Title: Cintredekin Besudotox
CAS Registry Number: 372075-36-0
CAS Name: Toxin hIL13-PE38QQR (plasmid phuIL13-Tx)
Additional Names: IL-13PE38
Literature References: Recombinant chimeric protein consisting of human interleukin 13 (IL-13) fused to a truncated form of Pseudomonas exotoxin A, PE38QQR; designed to target human epithelial carcinomas bearing the IL-13 receptor. Prepn: W. Debinski et al., J. Biol. Chem. 270, 16775 (1995); R. K. Puri et al., WO 9629417; eidem, US 5919456 (1996, 1999 both to U.S. Dept. Health Human Serv.). Review of pharmacology: S. R. Husain, R. K. Puri, J. Neuro-Oncol. 65, 37-48 (2003). Molecular mode of action study and gene expression profile: J. Han et al., ibid. 72, 35 (2005). Review of clinical experience in malignant glioma: N. G. Rainov, A. Söling, Curr. Opin. Mol. Ther. 7, 170-181 (2005).
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Immunotoxins.

Others monographs:
TCDDVigabatrinn-Amyl BromideToloxatone
OmeprazoleOxyfedrineDiflufenzopyrAluminum Benzoate
CrimidinePro-UrokinaseBenoxacorMatricarin
PlatinumPivampicillinChlormephosSodium Tungstate(VI)
©2016 DrugLead US FDA&EMEA